Xenon Pharmaceuticals Inc. financial data

Symbol
XENE on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 3650 Gilmore Way, Burnaby, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.47K % -5.49%
Debt-to-equity 4.33 % -3.99%
Return On Equity -24.2 % -3.56%
Return On Assets -23.2 % -3.76%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75.8M shares +18.1%
Common Stock, Shares, Outstanding 75.7M shares +18.8%
Entity Public Float 2.44B USD +29.9%
Common Stock, Value, Issued 1.44B USD +33%
Weighted Average Number of Shares Outstanding, Basic 77.7M shares +17.9%
Weighted Average Number of Shares Outstanding, Diluted 77.7M shares +17.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 178M USD +20.4%
General and Administrative Expense 59.6M USD +55.1%
Operating Income (Loss) -238M USD -27.6%
Nonoperating Income (Expense) 38.2M USD +65.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -199M USD -22.2%
Income Tax Expense (Benefit) -283K USD -145%
Net Income (Loss) Attributable to Parent -199M USD -21.6%
Earnings Per Share, Basic -2.75 USD/shares -9.56%
Earnings Per Share, Diluted -2.75 USD/shares -9.56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 137M USD +112%
Marketable Securities, Current 585M USD +23.1%
Accounts Receivable, after Allowance for Credit Loss, Current 853K USD -59.8%
Assets, Current 728M USD +33.7%
Deferred Income Tax Assets, Net 733K USD +64.7%
Property, Plant and Equipment, Net 10.1M USD +6.01%
Operating Lease, Right-of-Use Asset 8.57M USD -12.5%
Assets 884M USD +29.1%
Employee-related Liabilities, Current 6.2M USD +25.8%
Liabilities, Current 31.3M USD +11.1%
Operating Lease, Liability, Noncurrent 8.68M USD -15.6%
Liabilities 40M USD +3.96%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.21M USD +32.9%
Retained Earnings (Accumulated Deficit) -771M USD -34.8%
Stockholders' Equity Attributable to Parent 844M USD +30.6%
Liabilities and Equity 884M USD +29.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.2M USD -25.5%
Net Cash Provided by (Used in) Financing Activities 7.88M USD -93.4%
Net Cash Provided by (Used in) Investing Activities -46.2M USD -199%
Common Stock, Shares, Issued 75.7M shares +18.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -89.7M USD -831%
Deferred Tax Assets, Valuation Allowance 214M USD +30.2%
Operating Lease, Liability 10M USD -12.8%
Payments to Acquire Property, Plant, and Equipment 188K USD -91.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -198M USD -19.2%
Lessee, Operating Lease, Liability, to be Paid 11.4M USD -14.5%
Operating Lease, Liability, Current 1.35M USD +10.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.8M USD +2.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.74M USD +2.18%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Deferred Income Tax Expense (Benefit) 403K USD +39.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.39M USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.79M USD -2.5%
Deferred Tax Assets, Operating Loss Carryforwards 120M USD +48.7%
Preferred Stock, Shares Issued 0 shares -100%
Unrecognized Tax Benefits 10.9M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.09M USD -40.2%
Operating Lease, Payments 411K USD +1.23%
Preferred Stock, Shares Outstanding 0 shares -100%
Deferred Tax Assets, Net of Valuation Allowance 802K USD +57.6%